Prognostic and diagnostic role of PSA immunohistochemistry
Standard
Prognostic and diagnostic role of PSA immunohistochemistry : A tissue microarray study on 21,000 normal and cancerous tissues. / Bonk, Sarah; Kluth, Martina; Hube-Magg, Claudia; Polonski, Adam; Soekeland, Greta; Makropidi-Fraune, Georgia; Möller-Koop, Christina; Witt, Melanie; Luebke, Andreas M; Hinsch, Andrea; Burandt, Eike; Steurer, Stefan; Clauditz, Till S; Schlomm, Thorsten; Perez, Daniel; Graefen, Markus; Heinzer, Hans; Huland, Hartwig; Izbicki, Jakob R; Wilczak, Waldemar; Minner, Sarah; Sauter, Guido; Simon, Ronald.
in: ONCOTARGET, Jahrgang 10, Nr. 52, 10.09.2019, S. 5439-5453.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prognostic and diagnostic role of PSA immunohistochemistry
T2 - A tissue microarray study on 21,000 normal and cancerous tissues
AU - Bonk, Sarah
AU - Kluth, Martina
AU - Hube-Magg, Claudia
AU - Polonski, Adam
AU - Soekeland, Greta
AU - Makropidi-Fraune, Georgia
AU - Möller-Koop, Christina
AU - Witt, Melanie
AU - Luebke, Andreas M
AU - Hinsch, Andrea
AU - Burandt, Eike
AU - Steurer, Stefan
AU - Clauditz, Till S
AU - Schlomm, Thorsten
AU - Perez, Daniel
AU - Graefen, Markus
AU - Heinzer, Hans
AU - Huland, Hartwig
AU - Izbicki, Jakob R
AU - Wilczak, Waldemar
AU - Minner, Sarah
AU - Sauter, Guido
AU - Simon, Ronald
PY - 2019/9/10
Y1 - 2019/9/10
N2 - To assess the prognostic and diagnostic utility of PSA immunostaining, tissue microarrays containing 17,747 prostate cancers, 3,442 other tumors from 82 different (sub) types and 608 normal tissues were analyzed at two different antibody concentrations (1:100 and 1:800). In normal tissues, PSA expression was limited to prostate epithelial cells. In prostate cancers, PSA staining was seen in 99.9-100% (1:800-1:100) primary tumors, 98.7-99.7% of advanced recurrent cancers, in 84.6-91.4% castration resistant cancers, and in 7.7-18.8% of 16 small cell carcinomas. Among extraprostatic tumors, PSA stained positive in 0-3 (1:800-1:100) of 19 osteosarcomas, 1-2 of 34 ovarian cancers, 0-2 of 35 malignant mesotheliomas, 0-1 of 21 thyroid gland carcinomas and 0-1 of 26 large cell lung cancers. Reduced staining intensity and loss of apical staining were strongly linked to unfavorable tumor phenotype and poor prognosis (p < 0.0001 each). This was all the more the case if a combined "PSA pattern score" was built from staining intensity and pattern. The prognostic impact of the "PSA pattern score" was independent of established pre- and postoperative clinico-pathological prognostic features. In conclusion, PSA immunostaining is a strong prognostic parameter in prostate cancer and has high specificity for prostate cancer at a wide range of antibody dilutions.
AB - To assess the prognostic and diagnostic utility of PSA immunostaining, tissue microarrays containing 17,747 prostate cancers, 3,442 other tumors from 82 different (sub) types and 608 normal tissues were analyzed at two different antibody concentrations (1:100 and 1:800). In normal tissues, PSA expression was limited to prostate epithelial cells. In prostate cancers, PSA staining was seen in 99.9-100% (1:800-1:100) primary tumors, 98.7-99.7% of advanced recurrent cancers, in 84.6-91.4% castration resistant cancers, and in 7.7-18.8% of 16 small cell carcinomas. Among extraprostatic tumors, PSA stained positive in 0-3 (1:800-1:100) of 19 osteosarcomas, 1-2 of 34 ovarian cancers, 0-2 of 35 malignant mesotheliomas, 0-1 of 21 thyroid gland carcinomas and 0-1 of 26 large cell lung cancers. Reduced staining intensity and loss of apical staining were strongly linked to unfavorable tumor phenotype and poor prognosis (p < 0.0001 each). This was all the more the case if a combined "PSA pattern score" was built from staining intensity and pattern. The prognostic impact of the "PSA pattern score" was independent of established pre- and postoperative clinico-pathological prognostic features. In conclusion, PSA immunostaining is a strong prognostic parameter in prostate cancer and has high specificity for prostate cancer at a wide range of antibody dilutions.
U2 - 10.18632/oncotarget.27145
DO - 10.18632/oncotarget.27145
M3 - SCORING: Journal article
C2 - 31534629
VL - 10
SP - 5439
EP - 5453
JO - ONCOTARGET
JF - ONCOTARGET
SN - 1949-2553
IS - 52
ER -